Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.46 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601094 | 1.00 | CXCR2 (0.46) | CXCR2CX3CR1ALDH1A1ELANEACHE | |
| SCHEMBL4602573 | 0.83 | ACHE (0.44) | ALDH1A1ACHEBCHEAPPACP1 | |
| SCHEMBL4602578 | 0.83 | ACHE (0.44) | ALDH1A1ACHEBCHEAPPACP1 | |
| SCHEMBL4603852 | 0.81 | ALDH1A1 (0.46) | ALDH1A1ELANEACHEBCHEAPP | |
| SCHEMBL4632559 | 0.81 | ALDH1A1 (0.46) | ALDH1A1ELANEACHEBCHEAPP | |
| SCHEMBL14585691 | 0.81 | ALDH1A1 (0.46) | ALDH1A1ELANEACHEBCHEAPP | |
| SCHEMBL4603848 | 0.81 | ALDH1A1 (0.46) | ALDH1A1ELANEACHEBCHEAPP | |
| SCHEMBL14628425 | 0.80 | TACR3 (0.43) | CXCR2CX3CR1ALDH1A1ELANEACHE | |
| SCHEMBL4095030 | 0.78 | APP (0.60) | ALDH1A1ELANEACHEBCHEAPP | |
| SCHEMBL5531951 | 0.77 | HRH1 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924568-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1915351-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| WO-2007011623-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011623-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | TP53, TP53BP1, ACIN1 | CXCR2 1069/4885CX3CR1 2982/4885ALDH1A1 1994/4885 |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | TP53, ACIN1, TP53BP1 | CXCR2 592/4885CX3CR1 1770/4885ALDH1A1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.